NCT04854486 is a Phase 3 clinical trial of GSE and Xylitol in Covid19, sponsored by Larkin Community Hospital.

Who is sponsoring NCT04854486?

NCT04854486 is sponsored by Larkin Community Hospital.

What drugs are being tested in NCT04854486?

Interventions in NCT04854486: GSE and Xylitol, Control Placebo.

Is NCT04854486 still recruiting?

NCT04854486 is currently withdrawn. Last updated 16 October 2023.

Last reviewed 2023-10-16 · How we verify

NCT04854486

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients

Withdrawn Phase 3 Last updated 16 October 2023

What this trial tests

Phase 3 trial testing GSE and Xylitol in Covid19. Withdrawn.

Timeline

16 December 2021

Primary endpoint
30 March 2022

16 November 2022

Quick facts

Lead sponsor	Larkin Community Hospital
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Start date	16 December 2021
Primary completion	30 March 2022
Estimated completion	16 November 2022
Sites	2 locations across United States

Drugs / interventions tested

GSE and Xylitol
Control Placebo

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Larkin Community Hospital

Who can join

Adults 18 to 90, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial aims to ascertain the impact of GSE and Xylitol (XLEAR) in decreasing the time of negativisation in PCR testing in patients with COVID-19.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Larkin Community Hospital trials

Trials by the same sponsor.

NCT04610801 — Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2 · Phase 3 · withdrawn
NCT05032079 — Subzero and Scorpion Trial · NA · withdrawn
NCT04592705 — Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalize · Phase 1 · unknown
NCT04858620 — A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection · Phase 3 · withdrawn
NCT06084351 — Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection · Phase 3 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04854486 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Larkin Community Hospital
Last refreshed: 16 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04854486.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing